Chordate Medical has signed an agreement with another clinic for the Ozilia treatment for chronic migraine. The client is a specialist clinic in Munich, and Chordate’s market consultants in Germany have been handling the processing.
“Germany is one of the most important markets for Chordate, and this shows that we continue to convert prospects into orders there. Our market experts in Germany are continuing to work with a number of contacts from the fall conferences who have shown interest in Ozilia”, says Anders Weilandt, CEO of Chordate.
In November 2023, Chordate Medical entered into an agreement with a specialist clinic in Hamburg for Ozilia.
Chronic migraine in Germany
Migraine is one of the most common diseases worldwide; in Germany, approximately 12.5 million people suffer from migraine in some form. That is about one in seven Germans. Globally, it affects around 1.2 billion people. Between 1.5 and 1.8 million Germans have chronic migraine. Migraine and headache care in the country are among the most developed in Europe, and the market for migraine medications is one of the largest in the world. These conditions were part of the reason Chordate conducted its recently concluded clinical study in Germany.